Skye Bioscience, Inc. terminated the CBeyond trial, paused nimacimab research and development, and entered a conditional agreement to acquire Redx. Concurrent financing is expected to provide approximately $103.9 million, potentially increasing to $108.9 million.
SKYE · Skye Bioscience, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Skye Bioscience, Inc. said a jury returned a unanimous verdict in its favor on all claims in the Wendy Cunning lawsuit on November 10, 2026. Judgment is expected in due course, but the plaintiff may file post-trial motions or appeal.
Skye Bioscience said a jury returned a unanimous verdict in its favor on all claims in former employee Wendy Cunning’s whistleblower and retaliation lawsuit on November 10, 2026. Judgment is expected soon, but post-trial motions or an appeal remain possible.
Skye Bioscience proposes acquiring Redx Pharma Limited, renaming the combined company Fibrx Therapeutics, Inc., and seeking stockholder approval for related share issuances, financing, charter amendments, compensation and meeting adjournment.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SKYE
this stock
Skye Bioscience, Inc.
|
$4.56M | — | — | — | 2.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 31
Skye Bioscience, Inc. terminated the CBeyond trial, paused nimacimab research and development, and entered a conditional agreement to acquire Redx. Concurrent financing is expected to provide approximately $103.9 million, potentially increasing to $108.9 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SKYE | +12.1% | -36.8% | +6.2% | -19.5% | +37.4% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +16.0% | -31.3% | +9.7% | -16.2% | +30.3% |